Welcome to our dedicated page for Xbiotech SEC filings (Ticker: XBIT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing XBiotech Inc.’s SEC disclosures can feel like decoding laboratory notebooks. Clinical-stage updates on its True Human monoclonal antibody pipeline, GMP facility costs, and cash-burn projections sprawl across hundreds of pages. Whether you’re after “XBiotech SEC filings explained simply,” need an “XBiotech quarterly earnings report 10-Q filing,” or want “XBiotech 8-K material events explained,” this page is built for you.
Stock Titan’s AI-powered summaries convert the dense narrative of an “XBiotech annual report 10-K simplified” into a concise brief and provide instant “XBiotech Form 4 insider transactions real-time” alerts. Interactive dashboards add “XBiotech earnings report filing analysis,” while point-and-click navigation drops you straight into an “XBiotech proxy statement executive compensation” section—all without leaving the filings page. Real-time EDGAR monitoring ensures you see each 10-Q, 8-K, S-3, or SC 13G the moment it’s accepted.
Use these tools to monitor “XBiotech insider trading Form 4 transactions,” compare phase-based R&D spending, or flag new shelf registrations. By “understanding XBiotech SEC documents with AI,” biotech-focused investors can focus on trial milestones instead of pagination. Integrated watchlists also surface “XBiotech executive stock transactions Form 4” next to clinical timeline charts, giving you context for strategic moves as they occur.
XBiotech Inc. reported Q3 2025 results, posting a net loss of $6.0 million as operating expenses fell with no active clinical trials. Cash and cash equivalents were $147.4 million at September 30, 2025, supporting ongoing R&D and facility plans.
Research and development expense was $5.1 million in Q3 (down from $7.1 million), mainly from lower clinical and manufacturing activity. General and administrative expense was $1.0 million. Other income reflected $1.4 million of interest income and a $1.2 million foreign exchange loss. For the nine months, net loss was $18.6 million.
The company repaid in full a $10 million related-party convertible loan on January 31, 2025, extinguishing conversion rights. On October 2, 2025, XBiotech entered a new executive employment agreement with its CEO, providing a $1,250,000 base salary, eligibility for a $4,530,442 base bonus, and severance equal to three years of base salary and base bonus upon certain separations. Shares outstanding were 30,487,731 as of November 12, 2025.
XBiotech Inc. (XBIT) reported a Form 4 for director Craig Rademaker. On October 1, 2025, he received a nonstatutory stock option grant for 92,104 options with an exercise price of $2.64 per share under the company’s 2025 Equity Incentive Plan. The options relate to common stock and were acquired at no cost.
The options vest in two equal portions at four months and ten months from the grant date and carry a 10-year term expiring on October 1, 2035. Following the transaction, 92,104 derivative securities are beneficially owned directly.
XBiotech (XBIT) disclosed that director David Soffer reported a grant of 51,000 nonstatutory stock options at an exercise price of $2.64 per share. The award was granted on October 1, 2025 under the company’s 2025 Equity Incentive Plan. According to the filing, the options vest in two equal portions at four months and ten months from the grant date and carry a ten-year term, expiring on October 1, 2035. Following the grant, 51,000 derivative securities are beneficially owned, held directly.
XBiotech (XBIT) reported a director equity grant. On October 1, 2025, the reporting person received 79,115 nonstatutory stock options to purchase common stock at an exercise price of $2.64, equal to the closing sale price on the grant date. The options vest in two equal portions at four months and ten months from the grant date and carry a 10-year expiration. The filing lists the holder’s relationship as Director and shows direct (D) ownership.
XBiotech Inc. filed a Form 4 reporting a director stock option grant. On October 1, 2025, the reporting person received 56,000 nonstatutory options with a per‑share exercise price of $2.64 under the company’s 2025 Equity Incentive Plan.
The options vest in two equal portions at four months and ten months from the grant date and expire on October 1, 2035. Following the transaction, 56,000 derivative securities were beneficially owned directly.
Initial Form 3 filed for XBiotech Inc. (XBIT) by David Soffer, who identifies his relationship to the issuer as a director. The filing states that the reporting person does not beneficially own any securities of the issuer. The Form 3 is an initial Section 16 filing that discloses current ownership; in this case there are no non-derivative or derivative holdings reported.
Thomas Martin Kuendig, a director of XBiotech Inc. (XBIT), filed an initial Form 3 disclosing beneficial ownership of 300,000 shares of the issuer's common stock. The filing reports 200,000 shares held directly and two indirect holdings of 50,000 shares each attributed to his daughters, Stephanie Kuendig and Michelle Kuendig. The event requiring the statement is dated 08/29/2025 and the form is signed on 09/29/2025. No derivative securities are reported on this form.
Form 3 filed for XBiotech Inc. (XBIT) by Troy Tevi David, indicating his status as a director of the issuer. The filing states the date of the event requiring the statement as 08/29/2025 and discloses that no securities are beneficially owned by the reporting person at the time of filing. The form is signed and dated 09/29/2025.
FAQ
What is the current stock price of Xbiotech (XBIT)?
What is the market cap of Xbiotech (XBIT)?
